Key result
Cannabidiol reduces recurrent pericarditis pain by ~4 points at 8 weeks.
Why the study?
Recurrent pericarditis may involve inappropriate NLRP3 inflammasome activation, which pharmaceutically manufactured cannabidiol inhibits preclinical models, warranting clinical evaluation.
Does pharmaceutically manufactured cannabidiol improve patient-reported pericarditis pain in adults with symptomatic recurrent pericarditis?
Does pharmaceutically manufactured cannabidiol improve patient-reported pericarditis pain in adults with symptomatic recurrent pericarditis?
In a Phase 2 pilot trial, pharmaceutically manufactured cannabidiol was associated with significant reductions in pericarditis pain and systemic inflammation, allowing for tapering of background therapies.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This is real, prospective Phase II data showing a measurable pain and CRP signal in recurrent pericarditis, not proof that CBD works, since there was no placebo arm and the sponsor funded the trial. It is a strong enough signal to justify the randomized Phase III trial now underway, and not yet strong enough to change first-line treatment.”
“The central clinical lesson is not that CBD is now a proven pericarditis therapy, but that a mechanism-targeted, pharmaceutical-grade cannabinoid produced a measurable, biomarker-supported signal worth testing in a controlled trial, which is now underway.”
Should not yet change recurrent pericarditis management; leaves open whether cannabidiol merits placebo-controlled trials.
BACKGROUND: Recurrent pericarditis may be mediated through inappropriate activation of the NACHT, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome. Pharmaceutically manufactured cannabidiol is an oral formulation that inhibits NACHT, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome activation and development of pericarditis in a preclinical model. METHODS: This Phase 2, open-label, multicenter trial included adult patients with symptomatic recurrent pericarditis: pericarditis chest pain ≥4 on an 11-point numerical rating scale with an elevated C-reactive protein (≥1 mg/dL) or at least mild pericardial inflammation on cardiac magnetic resonance imaging. At enrollment, patients were on stable doses of non-steroidal anti-inflammatory drugs, colchicine, and/or corticosteroids. Cannabidiol was administered during an 8-week treatment period and an optional 18-week extension period when background therapy was tapered and discontinued. The primary efficacy end point was change in patient-reported pericarditis pain. Secondary end points included normalization of C-reactive protein and percentage of patients with recurrences. RESULTS: Among 27 patients (18 women, mean age 53 years), baseline maximal numerical rating scale pain score was 5.8±1.7, and 10 patients had elevated C-reactive protein. At Week 8, maximal numerical rating scale pain score was 2.1±1.8, and median time to numerical rating scale score ≤2 was 5 days. Among the 10 patients with baseline C-reactive protein elevation, C-reactive protein was normal at Week 8 in 8 patients (80%). During the extension period, 17 (71%) of 24 patients remained free of pericarditis recurrence. A serious adverse event leading to cannabidiol discontinuation occurred in 1 patient. CONCLUSIONS: In symptomatic patients with recurrent pericarditis, pharmaceutically manufactured cannabidiol appears safe and associated with reductions in pericarditis pain and systemic inflammation. REGISTRATION: URL: clinicaltrials.gov; Unique Identifier: NCT05494788.
No takes yet. Share an insight, caveat, or question.
Luis et al. (2026) studied Recurrent Pericarditis (n=27). Pharmaceutically manufactured cannabidiol was evaluated on Change in patient-reported pericarditis pain, using an 11-point NRS pain score, from baseline to Week 8. Pharmaceutically manufactured cannabidiol reduced the mean patient-reported pericarditis pain score by 3.7 points from baseline to 8 weeks in patients with symptomatic recurrent pericarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: